PharmaSGP Holding SE (PSG.DE)
EUR 24.8
(4.2%)
EUR 24.8
(4.2%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 40.91 Million EUR | 40.9% |
| 2022 | 17.59 Million EUR | 14.1% |
| 2021 | 15.42 Million EUR | -3.91% |
| 2020 | 16.04 Million EUR | -34.23% |
| 2019 | 24.4 Million EUR | 26.15% |
| 2018 | 19.34 Million EUR | 27.65% |
| 2017 | 15.15 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 6.32 Million EUR | -9.89% |
| 2024 Q2 | 6.64 Million EUR | -7.72% |
| 2023 Q2 | 6.26 Million EUR | 25.88% |
| 2023 Q1 | 4.97 Million EUR | 2.51% |
| 2023 FY | 24.79 Million EUR | 40.9% |
| 2023 Q4 | 7.01 Million EUR | -11.1% |
| 2023 Q3 | 7.89 Million EUR | 26.02% |
| 2022 Q4 | 4.85 Million EUR | -18.38% |
| 2022 Q3 | 5.94 Million EUR | 36.2% |
| 2022 Q2 | 4.36 Million EUR | 65.42% |
| 2022 Q1 | 2.64 Million EUR | -25.09% |
| 2022 FY | 17.59 Million EUR | 14.1% |
| 2021 Q1 | 1.56 Million EUR | 845.18% |
| 2021 Q4 | 3.52 Million EUR | -38.55% |
| 2021 Q3 | 5.73 Million EUR | 42.63% |
| 2021 FY | 15.42 Million EUR | -3.91% |
| 2021 Q2 | 4.02 Million EUR | 156.28% |
| 2020 Q2 | 5.21 Million EUR | 20.86% |
| 2020 FY | 16.04 Million EUR | -34.23% |
| 2020 Q4 | 166 Thousand EUR | -96.34% |
| 2020 Q3 | 4.53 Million EUR | -13.12% |
| 2020 Q1 | 4.31 Million EUR | -46.25% |
| 2019 Q1 | 3.76 Million EUR | 0.0% |
| 2019 FY | 24.4 Million EUR | 26.15% |
| 2019 Q4 | 8.02 Million EUR | 52.93% |
| 2019 Q3 | 5.24 Million EUR | -0.72% |
| 2019 Q2 | 5.28 Million EUR | 40.59% |
| 2018 FY | 19.34 Million EUR | 27.65% |
| 2017 FY | 15.15 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| MPH Health Care AG | 15.7 Million EUR | -160.599% |
| Apontis Pharma AG | -15.1 Million EUR | 370.954% |
| Dermapharm Holding SE | 182.89 Million EUR | 77.63% |
| Evotec SE | -47.5 Million EUR | 186.122% |
| MERCK Kommanditgesellschaft auf Aktien | 3.6 Billion EUR | 98.866% |
| SynBiotic SE | -7.58 Million EUR | 639.623% |